Condition: Primary Membranous Nephropathy · Sponsor: Everest Medicines (China) Co.,Ltd.
EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases. The overall aim of the study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of EVER001 in subjects with selected proteinuric glomerular diseases. The first targeted disease is primary membranous nephropathy.
This description comes directly from the study's public registry record.
Lixia Wang · 00862180123250 · lixia.wang@everestmedicines.com
Always discuss trial participation with your own doctor first.
| The Second Xiangya Hospital Of Central South University | Changsha, Changsha, China | Recruiting |
| The First Affiliated Hospital of PLA Army Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| The Third Affiliated Hospital,Sun Yat Sen University | Guangzhou, Guangdong, China | Recruiting |
| Peking University Shenzhen Hospital | Shenzhen, Guangdong, China | Recruiting |
| The Second Affiliated Hospital of Harbin Medical University | Harbin, Harbin, China | Recruiting |
| Xiangya Third Hospital, Central South University | Changsha, Hunan, China | Recruiting |
| The First Affiliated Hospital of Baotou Medical College | Baotou, Inner Mongolia, China | Recruiting |
| Zhongda Hospital Southeast University | Nanjing, Jiangsu, China | Recruiting |
| The Second Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| The Second Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| The First Affiliated Hospital of Medical college of Xi'an Jiaotong University | Xian, Shanxi, China | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05800873